GCTP Framework and Development of an Integrated Management System for Regenerative Medicine
First written in FY2023. 1 of 2 entries say "Softened", first in FY2024. Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024SoftenedAnnual report
「We will work to introduce a core business system and establish and build systems for logistics, the provision of information required for proper use, and the collection and management of data relating to trials and surveys if conditional and time-limited approval is granted.」
The filing does not state that the previously announced target of operating the integrated management system in the fiscal year ending March 2024 had been achieved. The introduction of the core business system and related measures are described as future issues without a deadline. - FY2023First statedAnnual report
「We are developing an integrated manufacturing and quality-control management system specialized in regenerative medicine that can manage multiple unprecedented projects, and aim to bring it into operation in the fiscal year ending March 2024 in order to achieve efficient management, including the CDMO business.」
The company planned to establish a manufacturing and quality-control system based on the GCTP ordinance and bring an integrated system for managing multiple projects and CDMO operations into use in the fiscal year ending March 2024.